At the news
? NEUTRALIMPACT 5/10 PRESS-RELEASE filed Nov 12, 2026 at 07:30 ET
Ascendis Pharma reported Q3 2026 product revenue of €366M (+89% YoY), driven by YORVIPATH (€291M, +103% YoY). GAAP EPS was €1.08 per diluted share, below the consensus estimate of $1.12 per ADS. The company achieved its first operating profit (€125M, 34% margin) and raised full-year operating cash flow guidance to at least €600M.
- Q3 2026 product revenue €366M, +89% YoY
- YORVIPATH revenue €291M, +103% YoY
- GAAP diluted EPS €1.08 vs consensus $1.12 (miss)
- Non-IFRS diluted EPS €1.71
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access